Free Trial
NASDAQ:BYSI

BeyondSpring (BYSI) Stock Price, News & Analysis

$1.96
-0.10 (-4.84%)
(As of 07/26/2024 ET)
Today's Range
$1.96
$2.10
50-Day Range
$1.91
$3.43
52-Week Range
$0.65
$4.00
Volume
13,294 shs
Average Volume
125,910 shs
Market Capitalization
$76.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BYSI stock logo

About BeyondSpring Stock (NASDAQ:BYSI)

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

BYSI Stock Price History

BYSI Stock News Headlines

Next opportunity for crypto millions
The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…
BeyondSpring Files 2023 Annual Report on Form 20-F
Next opportunity for crypto millions
The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…
BYSI Oct 2024 7.500 call
BYSI Mar 2024 7.500 call
BeyondSpring Inc BYSI
See More Headlines
Receive BYSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/29/2021
Today
7/27/2024
Next Earnings (Estimated)
7/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BYSI
Employees
80
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.75 million
Book Value
($0.91) per share

Miscellaneous

Free Float
27,590,000
Market Cap
$76.69 million
Optionable
Optionable
Beta
0.25
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Lan Huang Ph.D. (Age 53)
    Co-Founder, Chairman & CEO
  • Dr. June Lu Ph.D.
    Chief Scientific Officer
  • Mr. Linqing Jia
    Co-Founder
  • Stephen Kilmer
    Head of Investor Relations
  • Mr. Gregg Russo
    Senior Vice President of Human Resources

BYSI Stock Analysis - Frequently Asked Questions

How have BYSI shares performed this year?

BeyondSpring's stock was trading at $0.90 at the start of the year. Since then, BYSI stock has increased by 118.3% and is now trading at $1.9650.
View the best growth stocks for 2024 here
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) released its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.11. The firm earned $0.34 million during the quarter, compared to analysts' expectations of $0.34 million.

When did BeyondSpring IPO?

BeyondSpring (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

How do I buy shares of BeyondSpring?

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ) and Pfizer (PFE).

This page (NASDAQ:BYSI) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners